Full Text View
Tabular View
No Study Results Posted
Related Studies
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
This study is ongoing, but not recruiting participants.
Study NCT00039117   Information provided by National Cancer Institute (NCI)
First Received: June 6, 2002   Last Updated: April 4, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Leukemia, Myeloid
Leukemia, Myeloid, Acute
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
oblimersen sodium
cytarabine
daunorubicin hydrochloride
Additional drug interventions recognized in this trial
Daunorubicin
More general drug interventions related to this trial
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Arthur G. James Cancer Hospital &Richard J. Solove Research Institute
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services